Skip to main content

Time in Range News

Time in Range (TIR) is the percentage of time that a person spends with their blood glucose levels in the target range, usually between 70 and 180 mg/dl.

This study, now recruiting 350 participants, will examine the safety of the MiniMed 780G Advanced Hybrid Closed Loop System in people with type 1 diabetes (7+ Years)
The diaTribe team was on the ground at the 2019 ADA 79th Scientific Sessions to share several of the greatest highlights from the conference!
The latest updates on time-in-range goals for people with all types of diabetes, and insights linking FreeStyle Libre scanning frequency to outcomes.
Updates to the Clarity app allow G5 and G6 CGM users to set a daily time-in-range goal and be notified when it is reached, awesome Bright Spots pattern recognition in...
From clinical expertise and personal experience as a type 1, Dr. Sherr shares valuable (and exciting) perspectives on diabetes treatments.
MiniMed 780G to add automated correction boluses and Bluetooth, aims to launch by April 2020; Guardian Connect users can now use IQcast on Apple iPhones
Read about Kelly’s better quality of life on Loop, as well as the difficulties that ultimately ended her Looping experience; part 2 of a series on a hybrid-closed-loop...
Read about Adam’s time-in-range over two years on Loop – +2 hours/day! – along with quality of life changes, better sleep, and the mealtime impact. Part 1 of a series on...
Diabeloop’s automated insulin delivery system includes the Kaleido insulin pump, an Android controller, and the Dexcom G6 CGM; it is the second hybrid closed loop...
Tubeless Omnipod will communicate directly with Tidepool Loop app. Insulet’s own Horizon hybrid closed loop expected to launch in second-half of 2020
The SWITCH PRO trial will examine whether Tresiba improves blood sugar management more than Lantus, as measured by FreeStyle Libre Pro; now recruiting at 67 locations...
Control-IQ hybrid closed loop coming in summer 2019; paired app coming soon to the US; plans for the t:sport “patch” pump; and t:slim X2 pump launched outside the US
The benefits of measuring time in range, plus new care guidelines for adults with type 2 diabetes
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more
Read about a new cauliflower pizza crust, alongside updates on Senseonics Eversense CGM, Medtronic’s new CGM points program, the Beyond A1C movement, Tandem’s Basal-IQ,...
MiniMed 670G becomes the first hybrid closed loop system officially approved for type 1 pediatric use; systems are available now. European approval also received for 7...
Using time-in-range to assess risk for complications, Omnipod Horizon Closed Loop, Bihormonal closed loop (insulin + Pramlintide), SGLT-2 oral drug for type 1, and more!
The world’s first all-diabetes professional cycling team is now sponsored by Dexcom; diabetes research studies on CGM and exercise will start this year: What is the...
Farxiga and Sotagliflozin are the first pills to seek approval as add-ons to insulin for type 1; both bring strong time-in-range benefits, and if approved, might launch...
Get weekly email and phone notifications summarizing time-in-range and glucose trends from the updated Dexcom Clarity app

Pages